r Airway hyper-responsiveness in asthma is driven by excessive contraction of airway smooth muscle cells (ASMCs). influx. These data suggest that SOCE is the major Ca 2+ influx pathway for ASMCs with respect to sustaining agonist-induced airway contraction and the underlying Ca 2+ oscillations. The mechanisms of SOCE may therefore form novel targets for new bronchodilators.
r Sustained contraction and Ca 2+ oscillations require an influx of extracellular Ca 2+ , although the mechanisms and pathways mediating this Ca 2+ influx during agonist-induced ASMC contraction are not well defined.
r By inhibiting store-operated calcium entry (SOCE) or voltage-gated Ca 2+ channels (VGCCs), we show that SOCE, rather than Ca 2+ influx via VGCCs, provides the major Ca 2+ entry pathway into ASMCs to sustain ASMCs contraction and Ca 2+ oscillations.
r SOCE may therefore serve as a potential target for new bronchodilators to reduce airway hyper-responsiveness in asthma.
Abstract Asthma is characterized by airway hyper-responsiveness: the excessive contraction of airway smooth muscle. The extent of this airway contraction is proportional to the frequency of Ca 2+ oscillations within airway smooth muscle cells (ASMCs). Sustained Ca 2+ oscillations require a Ca 2+ influx to replenish Ca 2+ losses across the plasma membrane. Our previous studies implied store-operated calcium entry (SOCE) as the major pathway for this Ca 2+ influx. In the present study, we explore this hypothesis, by examining the effects of SOCE inhibitors (GSK7975A and GSK5498A) as well as L-type voltage-gated Ca 2+ channel inhibitors (nifedipine and nimodipine) on airway contraction and Ca 2+ oscillations and SOCE-mediated Ca 2+ influx in ASMCs within mouse precision-cut lung slices. We found that both GSK7975A and GSK5498A were able to fully relax methacholine-induced airway contraction by abolishing the Ca 2+ oscillations, in a manner similar to that observed in zero extracellular Ca 2+ ([Ca 2+ ] e ). In addition, GSK7975A and GSK5498A inhibited increases in intracellular Ca 2+ ([Ca 2+ ] i ) in ASMCs with depleted Ca 2+ -stores in response to increased [Ca 2+ ] e , demonstrating a response consistent with the inhibition of SOCE. However, GSK7975A and GSK5498A did not reduce Ca 2+ release via IP 3 receptors stimulated with IP 3 released from caged-IP 3 . By contrast, nifedipine and nimodipine only partially reduced airway contraction, Ca 2+ oscillation frequency and SOCE-mediated Ca 2+ influx. These data suggest that SOCE is the major Ca 2+ influx pathway for ASMCs with respect to sustaining agonist-induced airway contraction and the underlying Ca 2+ oscillations. The mechanisms of SOCE may therefore form novel targets for new bronchodilators. 
Introduction
Asthma is characterized by excessive airway smooth muscle (ASM) contraction (i.e. airway hyperresponsiveness; AHR). Although AHR has been clinically managed with bronchodilators and corticosteroids, these approaches are not always adequate for severe asthma and the development of new or alternative therapies would be beneficial. Unfortunately, efforts aiming towards this goal are hindered by a poor understanding of the aetiology of AHR Gauthier et al. 2015) . Consequently, in the present study, we focus on the fundamental Ca 2+ -dependent mechanisms of ASM contraction and how these may serve as novel targets for new bronchodilators.
ASM contraction is dependent on the phosphorylation of the regulatory myosin light-chain mediated by myosin light-chain kinase, which is activated by the binding of calmodulin and calcium (Pfitzer, 2001) . Hence, an increase of intracellular calcium concentration ([Ca 2+ ] i ) induces the contraction of ASM. Our previous studies have demonstrated that the pattern of increased [Ca 2+ ] i in ASM cells (ASMCs) induced by agonists consists of repetitive Ca 2+ waves propagating along the length of the ASMC, a phenomenon called Ca 2+ oscillations. Most importantly, the frequency of these Ca 2+ oscillations regulates the extent of ASM contraction (Perez & Sanderson, 2005; Bai & Sanderson, 2006a) .
The mechanism underlying these Ca 2+ oscillations relies on the cyclic release of Ca 2+ from (and re-uptake of Ca 2+ to) the sarcoplasmic reticulum (SR). Ca 2+ release mainly occurs via inositol-1,4,5-trisphosphate (IP 3 ) receptor Ca 2+ channels (IP 3 R) activated by IP 3 produced in response to agonist activation of phospholipase Cβ via G-protein coupled receptors. Ca 2+ re-uptake to SR occurs via SR Ca 2+ transport ATPases (SERCA) (Sathish et al. 2008; Prakash et al. 2009 ). Some Ca 2+ efflux also occurs via ryanodine receptors (RyRs) during the initial Ca 2+ oscillations Croisier et al. 2015) . Importantly, although the initiation of agonist-induced Ca 2+ oscillations does not require an influx of extracellular Ca 2+ , the maintenance of Ca 2+ oscillations, and thus sustained ASM contraction, does require Ca 2+ influx to replenish Ca 2+ lost across the plasma membrane (PM) mediated by PM Ca 2+ ATPases (Berridge et al. 2003) .
A variety of Ca 2+ entry pathways are proposed to contribute to Ca 2+ homeostasis in ASMCs including, but not limited to, voltage-gated Ca 2+ channels (VGCCs), receptor-operated Ca 2+ channels and reverse-mode Na + /Ca 2+ exchangers (Dai et al. 2006; Dai et al. 2007; Flores-Soto et al. 2013) . However, the most important Ca 2+ influx pathway coupled with Ca 2+ loss from SR is probably the store-operated calcium entry (SOCE). SOCE has been recently identified as a Ca 2+ influx pathway in ASMCs (Ay et al. 2004; Peel et al. 2006; Prakash et al. 2006; Peel et al. 2008; Sieck et al. 2008; Liu et al. 2010) . The mechanism mediating SOCE is multifaceted, involving a PM resident Ca 2+ channel called Orai1 and an SR membrane-spanning, Ca 2+ sensing protein called stromal interaction molecule (STIM) (Liou et al. 2005; Roos et al. 2005; Feske et al. 2006; Soboloff et al. 2012; Jairaman & Prakriya, 2013; Baba et al. 2014; Prakriya & Lewis, 2015; Steinckwich et al. 2015) . STIM detects decreases in Ca 2+ concentration within the SR ([Ca 2+ ] SR ), which induces the oligomerization and translocation of STIM to a region near the PM, where it interacts with Orai1 to generate a local Ca 2+ influx current (Lewis, 2007; Soboloff et al. 2012) .
Therefore, SOCE appears to be an appropriate Ca 2+ influx pathway that can be readily coupled to the decrease of [Ca 2+ ] SR occurring during agonist-induced Ca 2+ oscillations in ASMCs (Croisier et al. 2013) . Importantly, our mathematical studies predict that the Ca 2+ oscillation frequency of ASMCs is dependent on the magnitude of SOCE, rather than other Ca 2+ influx pathways (Croisier et al. 2013) , emphasizing SOCE as a key parameter for airway contraction. Furthermore, SOCE may be regulated by caveolin-1 (Sathish et al. 2012) , with linkage to CD38 and cyclic ADP ribose, indicating that the extent of SOCE may be enhanced with the upregulation of CD38 and caveolar protein during airway inflammation (Sathish et al. 2014) . Similarly, STIM aggregation in ASMCs has been shown to increase with inflammatory stimulation, again, suggesting a link between increased SOCE and AHR (Croisier et al. 2013; Wylam et al. 2015) . The obvious inverse corollary of these ideas is that a reduction in SOCE would reduce the Ca 2+ oscillation frequency of ASMCs to induce airway relaxation.
Consequently, to characterize the significance of SOCE in airway contraction and the underlying Ca 2+ oscillations of ASMCs, we tested the effects of two newly developed SOCE inhibitors, GSK7975A (G7) and GSK5498A (G5) (Ashmole et al. 2012; Derler et al. 2013; Rice et al. 2013) , as well as two classic L-type VGCC inhibitors, nifedipine and nimodipine, on agonist-induced airway contraction and Ca 2+ oscillations of ASMCs in mouse precision cut lung slices (PCLS). The effect of these drugs on SOCE mediated Ca 2+ influx was further confirmed in SOCE-activated PCLS. Our results show that SOCE, rather than VGCCs, is required for Ca 2+ influx to maintain agonist-induced Ca 2+ oscillations and the contraction of ASM. Thus, SOCE provides a potential novel target for new bronchodilators to reduce AHR.
Methods

Ethical approval
Animal maintenance and experimental procedures complied with the requirements of the Animal Welfare Act, US Public Health Service Policy and NIH guidelines and were approved by the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School. All experiments were performed on tissue collected immediately after death of animals not subject to any other treatments. All authors understand the ethical principles under which The Journal of Physiology operates and our work complied with the animal ethics policy and checklist as reported by Grundy (Grundy, 2015) .
Chemicals and reagents
GSK-7975A was obtained from Aobious Inc. (Gloucester, MA, USA); GSK-5498A was obtained from MedChem Express (Monmouth Junction, NJ, USA); Oregon Green 488 BAPTA-1 AM was obtained from Life Technologies (Grand Island, NY, USA); caged-iso-Ins(1,4,5)P 3 /propionoxymethyl ester (caged-IP 3 ) was obtained from Enzo Life Sciences (Farmingdale, NY, USA); ryanodine was obtained from Abcam Inc. (Cambridge, MA, USA); all other reagents were obtained from either Sigma-Aldrich (St Louis, MO, USA) or Thermo Fisher Scientific (Pittsburgh, PA, USA). Hanks' balanced salt solution (HBSS) was supplemented with 20 mM Hepes buffer (sHBSS) and adjusted to pH 7.4. Hanks' 0-Ca 2+ solution (0-Ca 2+ sHBSS) was prepared by supplementing HBSS without Ca 2+ with 20 mM Hepes, 0.9 mM MgSO 4 and 1 mM Na 2 H 2 -EGTA. The stock solutions for all compounds were prepared in DMSO with final working solutions containing 0.5% (or less) DMSO. Corresponding concentrations of DMSO were included in all control solutions.
Preparation of PCLS
The detailed protocol has been described previously (Perez & Sanderson, 2005) . Briefly, female Balb/c mice (8-12 weeks), purchased from Charles River Breeding Laboratories (Needham, MA, USA), were killed by cervical dislocation. After opening the thoracic cavity, the lungs were inflated with ß1 ml of 1.8% agarose in sHBSS at ß37
• C via an intratracheal catheter. Subsequently, ß0.3 ml of air was injected to flush the agarose within the airway into the distal alveoli. After the agarose was gelled by cooling the lungs with ß4
• C sHBSS, the lung lobes were removed and sectioned into ß180 μm thick slices with a vibratome (VF-300; Precisionary Instruments, Greenville, NC, USA). The PCLS were maintained in Dulbecco's modified Eagle's medium with antibiotics at 37
• C and 10% CO 2 for up to 3 days. All experiments were performed at 37
• C with constant perfusion using a custom-made, temperature-controlled microscope enclosure as described previously (Bai & Sanderson, 2006b ).
Measurement of airway contraction and relaxation
The detailed protocol has been described previously (Bai & Sanderson, 2009) . Briefly, PCLS were placed on a cover-glass that was mounted in a custom-made Plexiglas support, and held down by a 200 μm nylon mesh with a hole aligned over a selected airway. A perfusion chamber was created by placing another smaller cover-glass on the top of the nylon mesh and sealing the edges with silicone grease. Airway contraction and relaxation in response to different compounds was monitored with an inverted microscope (Diaphot; Nikon, Tokyo, Japan; or IX71; Olympus, Tokyo, Japan) with a 10× objective. Phase-contrast images were collected at a rate of one image per 2 s with a CCD camera, which was controlled by custom-programed software based on Video Savant 4 (IO Industries, Montreal, Canada). The change in lumen area of a selected airway was analysed using ImageJ (NIH, Bethesda, MD, USA) as described previously (Tan & Sanderson, 2014) .
To summarize drug-induced relaxation (%), we initially normalized the contractile state of an airway (measured at the mid-time point at 25 min in Figs 1-3) to its own initial contraction (measured at 15 min) by the formulae: % relaxation (R) = (area 25min -area 15min )/(100 -area 15min ). We then normalized the drug induced relaxation to the amount of relaxation that occurred in the control response by the formulae: % normalized relaxation = (R drug -R control )/(100 -R control ).
To characterize and compare rates of airway relaxation under various conditions, we calculated the time constant (t 1 ) for each response: each experimental airway contraction (from 15.5 to 35 min in Figs 1B, 2B, 2C and 3) was normalized to the initial control contractile response (at 15.5 min) and then subtracted from control contraction at each time point. This isolates the experimental-induced relaxation from the control J Physiol 595.10 relaxation. The time constant (t 1 ) of these relaxation data was calculated from the formula: y = y 0 + A 1 e −x/t 1 , where 'x' represents time, and 'y' represents the normalized contraction at each time point.
Measurement of intracellular Ca
2+ signalling PCLS were loaded with sHBSS containing 20 μM Oregon Green (OG) 488 BAPTA-1-AM, 0.1% Pluronic F-127 and 200 μM sulfobromophthalein (SB) in the dark at ß30
• C for ß1 h, followed by sHBSS containing 200 μM SB for an additional 30 min at room temperature to allow the de-esterification of OG. The intracellular Ca 2+ signalling of ASMCs in PCLS, mounted in the perfusion chamber (described above), was examined with either a custom-built, video-rate scanning confocal microscope or two-photon laser microscope (Perez & Sanderson, 2005; Bai & Sanderson, 2006b ). For real-time or time-lapse experiments, fluorescence images were recorded at a rate of 15 images per second, or at a rate of 1 image per 2 s, respectively, using custom-written image acquisition software based on Video Savant. The fluorescence intensity in a region of interest (8 × 10 pixels) within an ASMC, with respect to time, was determined using custom-written software. Relative fluorescence intensity was expressed as F t /F 0 , which is a ratio of the fluorescence intensity at a particular time (F t ) normalized to the initial time (F 0 ).
Flash photolysis of caged-IP 3
PCLS were initially incubated with OG as described above and subsequently incubated with sHBSS containing 4 μM Store-operated Ca 2+ entry in airway smooth muscle Ca 2+ oscillations 3207 caged-IP 3 , 0.1% Pluronic F-127 and 200 μM SB for 1 h, followed by de-esterification in sHBSS containing 200 μM SB for 30 min. Details of the flash photolysis set-up and protocols have been described previously (Leybaert & Sanderson, 2001; Tan & Sanderson, 2014) . Briefly, a pulse of UV light was generated from a mercury arc lamp with a band-pass filter (330 nm) and focused to a point into our custom-built confocal microscope. The intensity and duration of the flash, regulated by exposure time (300-1000 ms) and neutral density filters (with an optical density of 0.7-0.9), determined the amount of IP 3 released by photolysis of caged-IP 3 , and thereby the amount of Ca 2+ released from internal store via IP 3 R of SR. A UV exposure with the same intensity and duration was repeated three times in the same region of interest of an ASMC. Only the ASMCs that showed similar Ca 2+ signalling in response to the first and third exposures were used for analysis, suggesting a capacity to release similar small amounts of IP 3 for at least three times and the submaximal Ca 2+ signal response to each exposure. Different compounds were administrated to PCLS for 5 min before the second exposure, then followed by washout after exposure; the response of ASMC to the second exposure represents the effect of a specific compound on the IP 3 R pathway. The Ca 2+ -dependent fluorescence changes in ASMCs treated with different compounds were recorded and analysed as described above.
Preparation of SOCE-activated PCLS
This protocol and its validation have been demonstrated previously (Bai & Sanderson, 2006b ). Briefly, PCLS were simultaneously exposed to 20 mM caffeine and 25 μM ryanodine for 5 min, followed by a thorough washout with sHBSS prior to the experiments. 
Statistical analysis
All data are reported as the mean ± SEM; All differences between experimental groups were tested by ANOVA followed Tukey's honestly significant difference analysis; the sample number for statistical tests is provided where appropriate. P < 0.05 was considered statistically significant. Statistical analysis was performed with Origin 2016 software (OriginLab Corporation, Northampton, MA, USA).
Results
Response of airways to methacholine (MCh)
MCh was used as the agonist of choice throughout the present study to investigate the role of SOCE and L-type VGCCs in sustained agonist-induced contraction of airways; a concentration of 400 nM MCh was used to induce a non-saturated response of airway contraction and Ca 2+ oscillations in ASMCs as described previously (Perez & Sanderson, 2005; Bai & Sanderson, 2006a) . Activation of muscarinic receptors via MCh on other cell types, apart from ASMCs, in PCLS appeared to have no direct effect on airway contraction (Meurs et al. 2013) . Prior to the experiments, airway viability was confirmed by an initial exposure to MCh. The exposure of the PCLS to 400 nM MCh induced airway contraction with a lumen reduction of ß50-60% of the initial luminal area within 2 min. Removal of MCh resulted in an immediate airway relaxation that was completed within 5 min J Physiol 595.10 (Fig. 1) . The subsequent longer-duration exposure to MCh led to a similar airway contraction but one that slowly relaxed (t 1 = 930.9 ± 55.0 s) until a more stable lumen size of ß60% (of the initial size) was established. This state persisted for another 20 min when the agonist was present. This time-dependent control response was used to compare both the rate and magnitude of relaxation induced by various compounds and also the reversibility of action (Fig. 1B, MCh control) . To confirm airway viability at the end of each experiment, MCh and tested drugs were fully washed out and the airway was exposed for a third time to MCh (Fig. 1) .
Effect of an absence of extracellular Ca
2+
When extracellular Ca 2+ was removed (0-[Ca 2+ ] e ) to mimic a complete absence of Ca 2+ influx in the presence of 400 nM MCh, the contracted airway immediately underwent a rapid full relaxation (t 1 = 82.8 ± 1.5 s) and remained relaxed until extracellular Ca 2+ was restored (Fig. 1B, free calcium) . Under control conditions with 400 nM MCh, the airway displayed an absolute relaxation of ß21.7 ± 3.7 % (at 25 min); in 0-Ca 2+ , the airway displayed a normalized relaxation of 86.9 ± 8.6% (at 25 min). These data indicate that Ca 2+ influx was required to sustain airway contraction.
Effects of SOCE inhibitors on airway contraction
Treatment of MCh-contracted airways with SOCE blockers, G7 and G5 relaxed airway contraction in a concentration-dependent manner ( Fig. 2 ; see also Supporting information, Video S1). Specifically, the largest relaxation was induced by 100 μM G7 or G5, which relaxed the airway lumen by 84.5 ± 4.3% and 86.9 ± 2.2%, respectively. The magnitude of this relaxation was very similar to that induced by 0-Ca 2+ sHBSS, although the rate of relaxation was slower. G5 initially relaxed the airway at a faster rate (t 1 = 208.8 ± 1.7 s for 100 μM) compared to G7 (t 1 = 285.0 ± 1.3 s for 100 μM) (Fig. 2) . Lower concentrations of G7 or G5 induced less relaxation ( Fig. 2B and C) with an IC 50 of ß4.5 and ß1.5 μM, respectively (Fig. 4A) . Upon removal of G7 and G5, the airway re-contracted and an almost full re-contraction was achieved within 20 min ( Fig. 2B and C) . These data indicate that a near complete relaxation of airway contraction is induced when SOCE is inhibited and that these drug effects are reversible.
Effects of VGCC inhibitors on airway contraction
By contrast to SOCE inhibitors, treatment of MCh-contracted airways with the L-type VGCC inhibitors, nifedipine and nimodipine, only induced a partial relaxation of the airways (Figs 3 and 4A ), even at concentrations that were considered high relative to their normal efficacy (ß5-10 μM). Nifedipine, at concentrations ranging from 1 to 100 μM, relaxed the airway lumen up to 52.4 ± 7.6% (at 100 μM). However, although there was a significant difference compared to the control response, there was no significant difference between the responses induced by each concentration of nifedipine (Figs 3A and 4A) . Similarly, nimodipine relaxed the airway up to 33.8 ± 9.2% (at 100 μM) but, again, although there was a significant difference from the control response, there was no significant difference Figs 2 and 3 ) is normalized to its own control contraction (measured at 15 min). The time constant was calculated based on the relaxation induced by the maximal concentration (100 µM) of each drug; control indicates the base-line relaxation that occurred during sustained exposure to 400 nM MCh. Each point in A represents the mean ± SEM, data represent four to 12 airways for each point from at least 10 mice.
* P < 0.05, significant difference from nifedipine; # P < 0.05, significant difference from nimodipine; + P < 0. between the responses induced by each nimodipine concentration ( Figs 3B and 4A ). In addition, the rate of this relaxation was slow compared to G5 and G7 (t 1 for 100 μM nifedipine and 100 μM nimodipine were 471.2 ± 13.9 s and 972.7 ± 50.8 s, respectively, as summarized in Fig. 4B ). These non-significant results with increasing concentrations of nifedipine and nimodipine indicate that their efficacy rapidly reached saturation (ß10 μM) and suggest that the effects associated with higher concentrations are probably related to indirect mechanisms. Overall, as shown in Fig. 4 (Fig. 5D ). The addition of SOCE inhibitors G7 or G5 (G5 data not shown) after the initiation of MCh-induced Ca 2+ oscillations also inhibited the Ca 2+ oscillations ( Fig. 5E-H ; summarized in Fig. 6A) ; 100 (Fig. 5E) and 50 μM (Fig. 5F) and 38 ± 3 min −1 , respectively, after 5 min ( Fig. 5G and H) . A summary of the concentration-dependent inhibition of Ca 2+ oscillation frequency by G5 and G7 is provided in Fig. 6A . These data imply that a reduced Ca 2+ influx, as a result of SOCE inhibition, leads to slowing or cessation of Ca 2+ oscillations.
Effects of VGCC inhibitors on MCh-induced Ca
2+ oscillations
By contrast to the effects of 0-[Ca 2+ ] e , G7 or G5, the L-type VGCC inhibitors, nifedipine and nimodipine, did not induce the cessation of MCh-induced Ca 2+ oscillations at any concentration tested (up to 100 μM) ( Fig. 6B -E, nifedipine data not shown), even though these concentrations are relatively high with respect to their reported normal efficacy (ß5-10 μM). However, nifedipine and nimodipine induced a slowing of the Ca 2+ oscillation frequency from 54 ± 3 min −1 (control) to 36 ± 8 min −1 and 40 ± 4 min −1 , respectively, after 5 min of exposure at 100 μM ( Fig. 6A and B) . However, this decrease in frequency was similar to that induced by 10 μM nifedipine and nimodipine, again indicating that the response to VGCC inhibitors is not concentration-dependent above 10 μM (i.e. saturated at low concentrations). This partial effect on Ca 2+ oscillation frequency is consistent with the concentration independent relaxation effect (above 10 μM) of VGCC inhibitors on airway contraction (Figs 3 and 4) .
A possible explanation for the limited effect of nifedipine and nimodipine on airway contraction and Ca 2+ oscillation frequency is that these compounds are inactive in ASMCs of PCLS. To confirm that nifedipine and nimodipine were indeed capable of inhibiting VGCCs in PCLS, we tested their effect on KCl-induced Ca 2+ oscillations. Our previous studies have shown that these slow, depolarization-induced Ca 2+ oscillations are mediated by a constant Ca 2+ influx through VGCCs associated with a periodic overfilling of the SR with Ca 2+ and its release via RyRs by Ca 2+ -induced Ca 2+ release (Perez & Sanderson, 2005) . Accordingly, as shown in Fig. 6F , both nifedipine and nimodipine, at a 10-fold lower concentration (10 μM), quickly inhibited 50 mM KCl-induced Ca 2+ oscillations (within 20 s). These results suggest a high efficiency and specificity of these compounds for L-type VGCCs. By contrast, 100 μM G7 did not stop the KCl-induced oscillations within 10 min of exposure (Fig. 6G) , although some slowing in frequency was evident with longer exposure. This result suggests that KCl-induced oscillations do not utilize SOCE-mediated Store-operated Ca 2+ entry in airway smooth muscle Ca 2+ oscillations 3211 sHBSS containing 1.3 mM Ca 2+ was replaced. Thus, these ASMCs are considered 'SOCE-activated' , a condition that is irreversible and persists after the washout of caffeine and ryanodine (Bai & Sanderson, 2006b) , making these PCLS an ideal tool for assessing the effects of compounds on SOCE-mediated Ca 2+ influx. To evaluate the effect of G5 and G7 on SOCE, these inhibitors were applied when changing the [Ca 2+ ] e to zero and remained in place when the [Ca 2+ ] e was subsequently increased to 1.3 mM. An inhibition of SOCE is indicated by a reduced increase in F t /F 0 intensity upon Ca 2+ add-back ( Fig. 7B-E 
. Summary effects of SOCE inhibitor and VGCC inhibitor on MCh or KCl induced Ca 2+ oscillations in ASMCs
A, the concentration-dependent effect of SOCE inhibitors, GSK-7975A and GSK-5498A, and VGCC inhibitors, nifedipine and nimodipine, on the frequency of Ca 2+ oscillations induced by 400 nM MCh in ASMCs. B-E, representative Ca 2+ oscillation traces show that 400 nM MCh-induced Ca 2+ oscillations were partially slowed by nimodipine with concentrations ranging from 1 µM to 100 µM (representative of four to six from five mice). Note that, even at 100 µM B, nimodipine did not stop the MCh-induced Ca 2+ oscillations. F, a representative Ca 2+ oscillation traces show that 10 µM nifedipine stopped 50 mM KCl-induced Ca 2+ oscillations within 1 min (representative of five from four mice); G, 100 µM GSK-7975A did not stop 50 mM KCl-induced Ca 2+ oscillations after treatment for 10 min (representative of three from three mice). Representative traces are expressed as intensity (F t ) normalized to the initial intensity at t = 0 s (F 0 ), measured from a region of interest with size of 8 × 10 pixels within a single ASMCs. Each point in (A) represents the mean ± SEM, data represent four to 11 ASMCs for each point from at least 10 mice. * P < 0.05, significant difference from nifedipine; # P < 0.05, significant difference from nimodipine. [Colour figure can be viewed at wileyonlinelibrary.com] J Physiol 595.10
As shown in Fig. 7D and E (note the F t /F 0 intensity in last 5 min), G7 and G5 inhibited an increase in [Ca 2+ ] i of ASMCs in a concentration-dependent manner. Specifically, 100 μM G5 and G7 both fully prevented SOCE-mediated Ca 2+ increases upon the addition of 1.3 mM [Ca 2+ ] e (see Supporting information, Video S3). Lower concentrations of G7 and G5 partially inhibited SOCE-mediated increases with an IC 50 of 4.1 and 3.7 μM, respectively (Fig. 8A) . By contrast, the L-type VGCC inhibitors had only a small effect on SOCE-mediated increases in [Ca 2+ ] i in response to 1.3 mM [Ca 2+ ] e at all concentrations up to 100 μM (Fig. 8) .
Effects of SOCE blockers on the activation of the IP 3 R
An inhibition of Ca 2+ release by the IP 3 R could contribute to the decreased frequency of agonist-induced Ca 2+ oscillations as described previously (Tan & Sanderson, 2014) . To exclude this possibility, the action of G7 and G5 on IP 3 R sensitivity to IP 3 was evaluated by UV photolysis of caged-IP 3 in ASMCs. Under control conditions (in sHBSS), ASMCs displayed a transient Ca 2+ spike in response to a single UV flash. A similar Ca 2+ signal in the same ASMC was generated by a second and third UV flash, indicating that this approach was reproducible for at least three time trials (Fig. 9A) . As a positive control, the effect of 200 μM chloroquine, a type 2 bitter-taste receptor (TAS2R) agonist that attenuates the Ca 2+ release from SR via inhibition of IP 3 R (Tan & Sanderson, 2014) , was administrated to the PCLS for 5 min prior to the second flash. As shown in Fig. 9B and E, 200 μM chloroquine significantly reduced the amount of Ca 2+ released from SR by 43.5 ± 8.0%. However, treatment with either G7 or G5 (at 100 μM) had no effect on the IP 3 -induced Ca 2+ transient ( Fig. 9C-E) . These results support the notion Figure 8. Summary effects of SOCE inhibitors and VGCC inhibitors on SOCE-mediated Ca 2+ influx in SOCE-activated PCLS A, the concentration-dependent inhibitory effects of SOCE inhibitors, GSK-7975A and GSK-5498A, and VGCC inhibitors, nifedipine and nimodipine, on SOCE-mediated Ca 2+ influx in SOCE-activated PCLS. The % Ca 2+ influx for each compound is calculated by the average intensity F t /F 0 (AI) over a period from 19 min to 21 min normalized to its own control (the increased AI in response to the change of [Ca 2+ ] e from 0 to 1.3 mM). The effects of VGCC inhibitors, B nifedipine and C nimodipine, with concentrations ranging from 1 µM to 100 µM, on SOCE-mediated Ca 2+ influx in SOCE-activated PCLS. Note that the level of decreased [Ca 2+ ] i after 19 min indicates the inhibitory level of SOCE. Controls were treated with the vehicle of 0.5% DMSO in sHBSS. Traces are expressed as intensity (F t ) normalized to the initial intensity at t = 0 s (F 0 ), measured from a region of interest with size of 8 × 10 pixels within a single ASMCs. Each point in A represents the mean ± SEM, data represent three to six ASMCs for each point from at least 10 mice. Each line in B and C represents the mean and each point represents the mean ± SEM at select time points. Data in B represent three to five ASMCs for each line from four mice. Data in C represent three to four ASMCs for each line from four mice. * P < 0.05, significant difference from nifedipine; # P < 0.05, significant difference from nimodipine; + P < 0.05, significant difference from control. [Colour figure can be viewed at wileyonlinelibrary.com] that the cessation of Ca 2+ oscillations induced by G7 and G5 probably resulted from their inhibitory effect on SOCE-mediated Ca 2+ influx rather than decreased IP 3 R function.
Discussion
The molecular basis for SOCE, based on STIM and Orai1, was discovered almost a decade ago (Lewis, 2007) , although direct evidence for the role of SOCE in ASM contraction is limited. Ohga et al. (2008) showed that a SOCE inhibitor YM-58483/BTP-2 attenuated ovalbumin-induced bronchoconstriction in guinea pigs, implying an important role of SOCE in bronchoconstriction. However, the present study only provided indirect evidence in vivo or from tracheal muscle strips that might not represent the physiology of ASM from smaller airways surrounded by lung parenchyma. On the other hand, with a variety of Ca 2+ channels in the PM of ASM, the identity of the major pathway accounting for the SR refilling during agonist-induced ASM contraction remains controversial. Our previous mathematical modelling predicts that SOCE might be the major pathway (Croisier et al. 2013) . Therefore, we used mouse PCLS, which reflect the in situ physiology of ASM of relatively smaller airways, to investigate the effects of two specific SOCE inhibitors, G7 and G5, and two classical L-type VGCC inhibitors, nifedipine and nimodipine, on MCh-induced airway contraction and the underlying Ca 2+ oscillations within ASMCs.
We first confirmed the significance of Ca 2+ influx for sustained airway contraction with 0- [Ca 2+ ] e that mimics condition where Ca 2+ influx is totally absent. As predicted, MCh-induced airway contraction was quickly and almost completely relaxed when Ca 2+ influx could not occur. Next, we further examined the Ca 2+ oscillations in ASMCs, which mediate airway contraction by activating myosin light-chain kinase to induce the phosphorylation of regulatory myosin light-chain. In accordance with the contraction data, MCh-induced Ca 2+ oscillations in ASMCs also stopped quickly when there was no Ca 2+ influx.
To address which channel pathway accounts for this Ca 2+ influx, we first examined the effects of G7 and G5; these compounds are novel pyrazol derivatives that inhibit SOCE via both Orai1 and Orai3 with an IC 50 of approximately 4 μM in cell studies (Derler et al. 2013) . We found that both G7 and G5 (at 100 μM) almost fully relaxed the MCh pre-contracted airway and completely stopped MCh-induced Ca 2+ oscillations. These responses were extremely similar to those observed in 0- [Ca 2+ ] e , in terms of the extent and speed of relaxation. We also examined the role of SOCE on the initiation of Ca Representative Ca 2+ signal traces show that a single ASMC was exposed to a pulse of UV illumination (500 ms) during resting conditions (first flash), after 5 min of incubation (second flash) with either sHBSS (Cn, A, as negative control), 200 µM choloroquine (Ch, B, as positive control), 100 µM GSK-7975A (G7, C) and 100 µM GSK-5498A (G5, D), and after washout of the each compound (third flash). Note that only chloroquine inhibited the IP 3 -induced Ca 2+ signalling as shown in the summary of results in E. Traces are expressed as intensity (F t ) normalized to the initial intensity at t = 0 s (F 0 ), measured from a region of interest with a size of 8 × 10 pixels within a single ASMC. Each bar in E represents the mean ± SEM with four to nine ASMCs from three mice. * P < 0.05 indicates a significant difference from its own control in the first and third flash. ATPases. It is worth noting that, although G7 and G5 induced airway relaxation with an IC 50 of ß4.5 and ß1.5 μM, respectively (i.e. similar to the IC 50 tested in the cell studies), it appears that a concentration up to 100 μM is required for either G7 or G5 to induce a maximal effect on the PCLS. This dose is much higher than a dose expected in a cell study (ß10 μM) and probably is a result of the considerable thickness and more complex structure in the PCLS compared to the single cells.
The possibility that VGCC is an important contributor to Ca 2+ influx in ASM is supported by observations that VGCC inhibitors relaxed KCl-induced airway contraction, where it implies that ASM contraction results from membrane depolarization and an associated Ca 2+ influx via VGCCs Du et al. 2006 (Janssen, 2002) and our data obtained in the present study, as well as those from previous studies (Perez & Sanderson, 2005) , are consistent with this hypothesis in that neither airway contraction, nor Ca 2+ oscillations induced by MCh can be completely inhibited by nifedipine or nimodipine (up to 100 μM). The possibility that nifedipine or nimodipine were inactive is ruled out by their clear ability, at low concentrations, to inhibit KCl-induced Ca 2+ oscillations. Nevertheless, a similar partial airway relaxation and limited reduction in Ca 2+ oscillation frequency was observed with all concentrations of VGCC inhibitors. These results imply that the activity of VGCCs accounts for a relatively small amount of Ca 2+ influx during agonist-induced Ca 2+ oscillations. Given that the agonist-induced Ca 2+ oscillations might only result in a gradual decrease in [Ca 2+ ] SR rather than a full depletion of the SR Ca 2+ (Croisier et al. 2013) content. The slowing of KCl-induced Ca 2+ oscillations with longer exposure of G7 may result from the limited non-specific action of G7 on VGCCs (Derler et al. 2013) , even though this inhibitory effect appeared to be much weaker than that provided by nifedipine. Therefore, the relatively specific inhibition of SOCE via G7 or G5, together with the inability of VGCCs to either compensate or match for the inhibited SOCE, resulted in almost complete cessation of the agonist-induced Ca 2+ oscillations and thus full airway relaxation. It is important to note that, although the full airway relaxation takes time to develop, the cessation of Ca 2+ oscillations was, to some extent, more rapid. This observation can be explained by the fact that the generation of Ca 2+ oscillations require a threshold level of Ca 2+ influx (Croisier et al. 2013 ), which could not be provided when SOCE was blocked via G7 or G5. However, a small amount of Ca 2+ influx via VGCCs and other Ca 2+ influx pathway might still exist to account for a weak but persistant airway contraction until the intracellular Ca 2+ is totally run down.
To further corroborate that G7 and G5 were acting on SOCE, we utilized SOCE-activated PCLS in which a persistent Ca 2+ influx was generated by full Ca 2+ depletion of the SR (Bai & Sanderson, 2006b ). Compared to the previous techniques that stimulate SOCE by inhibiting J Physiol 595.10 SERCA (e.g. using thapsigargin), this approach preserves the activity of SERCA, which appears to circumvent the commonly observed inactivation of SOCE by locally accumulated [Ca 2+ ] i . Our data indicate that both G7 and G5 inhibited the elevation of [Ca 2+ ] i at the same time as increasing [Ca 2+ ] e from 0 to 1.3 mM, supporting the idea that they act via an inhibition of SOCE. By contrast, neither nifedepine, nor nimodipine (up to 100 μM) could prevent the increase of [Ca 2+ ] i in response to higher [Ca 2+ ] e , indicating that these compounds have little effect on SOCE. These observations further support the idea that G7 and G5 stop agonist-induced airway contraction and underlying Ca 2+ oscillation by inhibiting SOCE-mediated Ca 2+ influx. Interestingly, another widely accepted SOCE inhibitor, Synta66, appeared to show little effect on 400 nM MCh-induced airway contraction in PCLS (data not shown). Synta66 has been suggested to block the CRAC current (I CRAC ) in many cell studies (Ng et al. 2008; Li et al. 2011; Derler et al. 2013; Samanta et al. 2014) . However, it failed to inhibit a bronchoconstriction of human bronchial rings induced by MCh (Ashmole et al. 2012) , as well as an aorta contraction of mouse aorta ring evoked by α 1 -adrenoceptor agonist (Li et al. 2011) . These studies, together with our observation, imply that Synta66 might not be able to provide efficient inhibition of I CRAC in smooth muscle tissue.
The mechanism mediating agonist-induced Ca 2+ oscillation involves Gα q -activated phospholipase Cβ in response to agonist-stimulated G-protein coupled receptors, coupling to phosphatidylinositol 4,5-bisphosphate to produce IP 3 , which further binds to IP 3 R on SR to induce a repetitive Ca 2+ release from an internal store to form Ca 2+ oscillations (Berridge et al. 2003; Foskett et al. 2007) . Previous studied showed that the decreased interaction of IP 3 with the IP 3 R would also inhibit agonist-induced Ca 2+ oscillations (Tan & Sanderson, 2014) . Therefore, to rule out the possibility that the G7 and G5 stopped MCh-induced Ca 2+ oscillations by inhibiting the IP 3 R pathway, we investigated the effect of G7 and G5 on activation of IP 3 R using agonist independent IP 3 released by UV photolysis of caged-IP 3 . We showed that neither G7, nor G5 had effect on increased [Ca 2+ ] i in response to released IP 3 , confirming a normal IP 3 R function in the presence of G7 or G5.
Taken together, our findings demonstrate the greater importance of SOCE, with respect to L-type VGCCs, for the Ca 2+ influx required by sustained agonist-induced airway contraction and the underlying Ca 2+ oscillations. A major implication of this finding is that the inhibition of SOCE might be a novel drug target for the treatment of diseases characterized by excessive ASM contraction, such as asthma and chronic obstructive pulmonary disease.
